证券日报网讯 2月26日，采纳股份发布公告称，公司控股子公司江西丰临医疗科技股份有限公司及其全 资子公司江西丰临医用器械有限公司，于近日收到国家知识产权局颁发的专利证书。 （文章来源：证券日报） ...

2月26日，采纳股份发布公告，公司控股子公司江西丰临医疗科技股份有限公司及其全资子公司江西丰 临医用器械有限公司，于近日收到国家知识产权局颁发的发明专利证书，专利名称为"一种防针刺安全 留置针组装设备"。上述专利为控股子公司自主研发，其所涉及技术均与控股子公司主营业务产品技术 相关，专利权自授权公告之日起生效。 ...

证券代码：301122 证券简称：采纳股份 公告编号：2026-011 采纳科技股份有限公司 上述专利的取得和运用，不会对公司短期的经营业绩构成重大影响，但有利 于公司进一步完善知识产权保护体系，形成持续创新机制，保持技术的领先地位， 提升公司的核心竞争力。 特此公告。 采纳科技股份有限公司董事会 2026 年 2 月 26 日 1 / 1 关于控股子公司取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）控股子公司江西丰临医疗科技 股份有限公司（以下简称"丰临医疗"）及其全资子公司江西丰临医用器械有限 公司（以下简称"丰临医用"），于近日收到国家知识产权局颁发的专利证书， 具体情况如下： | 序号 | 专利名称 | 专利类型 | 专利号 | 专利权人 | 授权公告日 | | | --- | --- | --- | --- | --- | --- | --- | | 1 | 一种防针刺安全留 | 发明专利 | ZL | 丰临医疗 | 2026 年 月 | 02 | | | 置针组装设备 | | 20231 ...

（文章来源：证券日报） 证券日报网讯 2月25日，采纳股份在互动平台回答投资者提问时表示，截至2026年2月13日，公司股东 数为6903户。 ...

证券代码：301122 证券简称：采纳股份 公告编号：2026-010 采纳科技股份有限公司 关于部分募集资金专户完成销户的公告 1 / 3 | | | | 产业园建设项目 | | | --- | --- | --- | --- | --- | | 3 | 江苏江阴农村商业银行 股份有限公司祝塘支行 | 018801240018202 | 研发中心建设项目 | 已注销 | | 4 | 中国农业银行股份有限 公司江阴华士支行 | 10641401040019320 | 补充流动资金项目 | 已注销 | | 5 | 招商银行股份有限公司 江阴支行 | 511902989110201 | 超额募集资金 | 已注销 | | 6 | 宁波银行股份有限公司 江阴支行 | 78040122000429159 | 超额募集资金 | 已注销 | | 7 | 上海浦东发展银行江阴 | 92060078801400000785 | 年产 9.2 亿支（套） 医用注射穿刺器械 | 已注销 | | | 澄东支行 | | 产业园建设项目 | | | 8 | 江苏江阴农村商业银行 股份有限公司祝塘支行 | 018801240018426 ...

转自：前瞻产业研究院 以下数据及分析来自于前瞻产业研究院宠物芯片研究小组发布的《中国宠物行业（宠物经济）市场前景预测 与投资战略规划分析报告》。 行业主要公司：采纳股份(301122.SZ);康德莱(603987.SH);威高股份(01066.HK);正川股份(603976.SH);山东药 玻(600529.SH);旗滨集团(601636.SH);凯盛科技(600552.SH)等。 本文核心数据：宠物芯片政策汇总;政策解读;发展目标汇总等。 1、政策历程图 中国宠物芯片行业政策早期2010年国内多个地方开启了宠物芯片植入的试点工作，当时各地试点多聚焦于犬 只管理，核心是解决城市养犬统计难、识别难以及狂犬病防疫追溯等问题，且不同地区的试点方案在实施时 间、收费标准和服务细节上各有差异。2019年多个地方密集出台或落地实施《养犬管理条例》，这些条例普 遍强化了养犬登记、免疫管理，且不少地区明确将电子标识(宠物芯片)植入作为核心管理手段，以此规范养 犬行为、保障公共安全。2024年深圳市犬只电子标签植入管理规定(试行)，规定除病犬、孕犬、年龄小于3 个月或体重低于2公斤的幼犬外，深圳所有犬只均应当植入电子标签。确实 ...

Core Viewpoint - The company, Canar Medical, is experiencing a decline in revenue and profit, with a significant reliance on overseas sales benefiting from the depreciation of the RMB [3][7]. Group 1: Company Overview - Canar Medical specializes in the research, production, and sales of injection and puncture instruments, as well as laboratory consumables, with main products including puncture needles, syringes, laboratory consumables, and masks [2][7]. - The company began supplying IVF culture tubes to Thermo Fisher in 2018 [2]. - As of January 30, the number of shareholders is 6,957, a decrease of 2.08%, while the average circulating shares per person increased by 2.13% [7]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On February 13, Canar Medical's stock price fell by 0.06%, with a trading volume of 61.59 million yuan and a turnover rate of 2.52%, resulting in a total market capitalization of 3.911 billion yuan [1]. - The stock has seen a net inflow of 2.74 million yuan from major investors today, with a ranking of 19 out of 138 in its industry, although the industry overall has experienced a net outflow of 461 million yuan [4][5]. Group 4: Technical Analysis - The average trading cost of the stock is 28.95 yuan, with the stock price currently near a support level of 31.49 yuan, indicating potential for a rebound if this level holds [6].

证券代码：301122 证券简称：采纳股份 公告编号：2026-009 采纳科技股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十八次 会议、2026 年第一次临时股东会，分别审议通过了《关于使用部分闲置募集资 金和自有资金进行现金管理的议案》，同意公司及全资子公司在确保不影响募集 资金投资项目和公司正常经营，并有效控制风险的前提下，使用额度不超过人民 币 2,000 万元（含本数）的闲置募集资金和额度不超过人民币 80,000 万元（含 本数）的自有资金进行现金管理。使用期限自股东会审议通过之日起 12 个月内 有效。在上述额度和期限内，资金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的相关公告。 注：公司与上述受托方无关联关系。 一、本次使用部 ...

Core Viewpoint - The company, Canar Medical, has seen a stock price increase of 3.14% with a trading volume of 140 million yuan and a market capitalization of 3.897 billion yuan, benefiting from the depreciation of the RMB and its focus on the medical device sector, particularly in assisted reproduction [1][2][3]. Company Overview - Canar Medical Co., Ltd. specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables. The main products include puncture needles, syringes, laboratory consumables, and masks [2][7]. - The company began supplying IVF culture tubes to Thermo Fisher in 2018, indicating a strategic partnership in the assisted reproduction market [2]. - As of January 30, the number of shareholders is 6,957, a decrease of 2.08%, with an average of 10,872 circulating shares per person, an increase of 2.13% [7]. Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Market Position and Trends - The company has a high overseas revenue ratio of 90.61%, benefiting from the depreciation of the RMB [3]. - The average trading cost of the stock is 28.77 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak. The current stock price is near a support level of 31.49 yuan, which is critical for potential rebound or further decline [6].

Group 1 - The core point of the article is that the company, CaiNa Technology Co., Ltd., has received a patent for a "backflow prevention blood collection needle" from the National Intellectual Property Administration of China [1] - The patent was granted to Jiangsu CaiNa Medical Technology Co., Ltd., a wholly-owned subsidiary of CaiNa Technology [1] Group 2 - The article also highlights the trend of young executives, specifically those born in the 2000s, taking on significant roles in A-share companies, which poses a challenge to meet investor expectations [1] - A specific example mentioned is a 26-year-old who has recently returned from studying at a prestigious American university and has assumed the roles of chairman and general manager [1]